GlassScriptPhysician profile
Justin Laface
NPI 1740805092
$1,274.25
in general payments reported to CMS, 2019-2025
16 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.11 · 2024: $900 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $469.95 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pulmonx Corporation | $146.33 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Penumbra, INC. | $144.38 | 2024 | Ruby Coil |
| Glaxosmithkline, LLC. | $122.88 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $82.94 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $72.55 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $59.00 | 2025 | Tezspire |
| Philips North America LLC | $36.00 | 2025 | Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $18.81 | 2025 | Lumryz |
| Genentech USA, INC. | $18.51 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $18.33 | 2024 | Aralast |
| Azurity Pharmaceuticals, INC. | $17.90 | 2025 | Alvesco |
| Electromed, INC. | $17.83 | 2025 | Smartvest |
| Verona Pharma, INC. | $16.82 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $16.11 | 2023 | Ozempic, Rybelsus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.91 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Laface listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.